Chronic migraine: Common anesthetic could provide relief

For someone living with chronic migraine, a pain-free day can feel less like an ordinary Tuesday and more like winning a small lottery. Chronic migraine can bring headache, nausea, sensitivity to light and sound, brain fog, and fatigue on so many days that planning work, family time, exercise, or even a trip to the grocery store starts to require military-level logistics.

That is why researchers have been paying attention to an unexpected treatment candidate: lidocaine, the familiar local anesthetic commonly used to numb tissue during medical and dental procedures. In specialized headache centers, intravenous lidocaine has been investigated as a way to interrupt severe, persistent migraine in people whose symptoms have not improved with conventional treatments.

The results are intriguing. A large retrospective study of hospitalized patients with refractory chronic migraine found substantial short-term reductions in pain after several days of intravenous lidocaine therapy. More recent clinical guidance published in 2026 continues to recognize IV lidocaine as a possible inpatient option for difficult-to-treat migraine, although the quality of evidence remains limited. Translation: there is genuine medical interest here, but nobody should be ordering a bottle of lidocaine and an IV pole from the internet.

What is chronic migraine?

Migraine is a neurological disorder, not simply a particularly rude headache. Along with head pain, attacks can cause nausea, vomiting, dizziness, extreme fatigue, difficulty concentrating, and sensitivity to light, noise, movement, or smells.

Doctors generally diagnose chronic migraine when a person has headaches on at least 15 days per month for more than three months, with migraine features occurring on at least eight of those days. Some people experience a recognizable throbbing attack on certain days and a lower-grade background headache on others.

The condition can evolve from episodic migraine, in which attacks occur less frequently. Factors associated with chronification include a high baseline number of migraine attacks, sleep problems, obesity, stress, and frequent use of acute headache medications. Medication overuse deserves special attention because repeatedly treating headaches with certain pain relievers, combination medications, triptans, or opioids can paradoxically contribute to even more headache days.

When migraine becomes refractory

Most people with migraine can find at least some benefit from combinations of acute medication, preventive therapy, lifestyle adjustments, or procedures. A smaller group remains severely symptomatic despite trying multiple appropriate treatments. Clinicians often describe these cases as refractory or intractable migraine.

These are not people who skipped one ibuprofen tablet and declared defeat. Many have cycled through multiple preventive drugs, CGRP-targeted therapies, Botox injections, triptans, gepants, neuromodulation, behavioral strategies, and other approaches while continuing to experience disabling symptoms.

When a prolonged or extremely severe migraine cycle does not respond to outpatient treatment, hospitalization at a specialized headache center may sometimes be considered. That is the setting in which intravenous lidocaine has attracted particular interest.

Why would an anesthetic help migraine?

Lidocaine is best known as a local anesthetic. Dentists use related preparations to make procedures much less memorable, and physicians routinely use lidocaine to numb areas before injections, stitches, and minor surgery.

Its biological effects extend beyond temporarily numbing skin, however. Lidocaine blocks voltage-gated sodium channels involved in the generation and transmission of nerve signals. When delivered systemically under carefully controlled conditions, it can influence pain-processing pathways throughout the nervous system.

Migraine involves abnormal activation and sensitization of complex neurological pathways, including the trigeminovascular system. Researchers have proposed that intravenous lidocaine might reduce neuronal excitability, interfere with pain transmission, and potentially influence inflammatory or sensitization processes associated with persistent headache.

Exactly why some people with refractory migraine respond remains uncertain. Migraine biology has never been particularly interested in making life simple for researchers.

What did the major lidocaine study find?

One of the most frequently discussed investigations was a retrospective analysis involving 609 hospital admissions for refractory chronic migraine. The patients were treated at a specialized headache center and received continuous intravenous lidocaine during hospitalization.

Before treatment, the median headache pain rating was 7 out of 10. By the end of hospitalization, the median rating had fallen to 1 out of 10. Approximately 87.8% of patients qualified as acute responders, defined by the investigators as achieving a clinically meaningful reduction in pain.

The treatment was not necessarily a permanent migraine eviction notice. At follow-up roughly one month later, 43% of evaluated patients were sustained responders. Average headache frequency among patients with available follow-up information decreased from approximately 26.8 headache days per month to 22.5 days.

That reduction may sound modest to someone without chronic migraine. To a patient who has spent years experiencing a headache nearly every day, several additional functional days can matter enormously.

There is an important catch

The study was observational and retrospective rather than a randomized, placebo-controlled clinical trial. Patients also received other treatments during hospitalization, including drugs such as magnesium, ketorolac, corticosteroids, and neuroleptic medications when clinically appropriate.

Consequently, researchers cannot say with certainty that lidocaine alone produced the improvement.

There was also incomplete follow-up data. People who felt dramatically betteror dramatically worsecould theoretically have been more or less likely to return, introducing bias into the results.

The correct interpretation is therefore not “lidocaine cures chronic migraine.” A better summary is: IV lidocaine appears capable of helping some patients with extremely difficult-to-treat migraine, and the results are strong enough to justify continued research.

What does newer guidance say about IV lidocaine?

The story did not end with the 2022 retrospective study. A multidisciplinary practice advisory on intravenous management of hospitalized headache patients, published in final journal form in 2026, reviewed available evidence for treatments used when headache disorders become severe or intractable.

The panel concluded that intravenous lidocaine may benefit hospitalized patients with intractable migraine and certain other headache disorders, but characterized the certainty of the evidence as low. The recommendation therefore remains cautious rather than enthusiastic.

The advisory also emphasizes that continuous lidocaine administration requires an appropriately equipped medical environment. Cardiovascular monitoring, clinicians experienced with the medication, and immediate access to treatment for local anesthetic systemic toxicity are important safety considerations.

The experts advised that continuous IV lidocaine treatment generally should not extend beyond five days because a potentially toxic metabolite can accumulate during prolonged infusion. In selected circumstances, serum drug-level monitoring may also be considered.

In other words, this is highly supervised inpatient medicinenot a migraine life hack.

What side effects can occur?

In the large refractory migraine study, nausea and vomiting were among the most commonly reported adverse effects and were generally mild. Other reports and clinical experience with systemic lidocaine describe potential neurological and cardiovascular effects.

Depending on dose, blood concentration, individual susceptibility, and other medical factors, possible symptoms can include:

• Nausea or vomiting
• Dizziness or lightheadedness
• Tingling or numbness
• Visual disturbances
• Confusion or unusual neurological sensations
• Changes in blood pressure or heart rhythm
• Rare but potentially serious local anesthetic systemic toxicity

This safety profile explains why prolonged IV lidocaine infusions belong in hospitals or specialized treatment facilities with appropriate monitoring.

Lidocaine can be used for migraine in several different ways

Intravenous infusion is only one method researchers and headache specialists have explored. Seeing the word “lidocaine” in two migraine treatments does not mean those procedures are interchangeable.

Greater occipital nerve blocks

A clinician can inject a small amount of local anesthetic around the greater occipital nerve near the back of the head. NYU Langone and other headache centers use nerve blocks as an acute or bridging treatment for selected patients.

Randomized research has also produced encouraging findings. In a placebo-controlled study of chronic migraine, bilateral greater occipital nerve blocks containing 2% lidocaine given every four weeks for 12 weeks reduced headache and migraine days more effectively than saline injections and were generally well tolerated.

The evidence base for nerve blocks is not perfect, and protocols vary between clinics, but this approach is considerably different from circulating lidocaine through the bloodstream for days.

Intranasal lidocaine

Lidocaine has also been administered through the nose in an attempt to influence structures such as the sphenopalatine ganglion. Research results have been mixed. Some trials and reviews have suggested rapid benefit in selected patients, while other controlled studies found little or no advantage over placebo.

That inconsistency is another reminder that route, dose, patient selection, concurrent medications, and migraine subtype all matter.

Middle meningeal artery lidocaine: an emerging approach

A newer and much more experimental strategy involves delivering lidocaine directly into the middle meningeal artery, a vessel associated with the pain-sensitive coverings surrounding the brain.

A small 2025 study followed eight people with refractory migraine treated with intra-arterial lidocaine. Disability scores improved substantially over three months, with five of eight participants achieving at least a 50% reduction in their MIDAS disability scores. The sample was tiny, however, so these findings should be viewed as early-stage evidence rather than confirmation of effectiveness.

Other early clinical work has continued investigating localized middle meningeal artery treatment. This field is fascinating, but it remains specialized and experimental.

How does lidocaine compare with standard chronic migraine treatment?

For the vast majority of people with chronic migraine, IV lidocaine is nowhere near the beginning of the treatment ladder.

Doctors usually build an individualized plan that combines acute treatment with prevention. Depending on medical history, symptoms, previous treatment response, pregnancy considerations, cardiovascular risk, insurance coverage, and other factors, options may include:

• Triptans for suitable patients
• Gepants and other migraine-specific acute medications
• Anti-inflammatory medicines
• Anti-nausea medication
• Preventive medicines such as topiramate or certain blood pressure medications
• CGRP-targeted monoclonal antibodies or preventive gepants
• OnabotulinumtoxinA (Botox) for chronic migraine
• Neuromodulation devices
• Nerve blocks in selected patients
• Behavioral treatment, including relaxation strategies, biofeedback, or cognitive behavioral therapy
• Regular sleep, meals, hydration, physical activity, and management of individual triggers

The FDA has approved numerous medications for treating or preventing migraine, while Botox has an established role specifically in chronic migraine. CGRP-targeted therapies have dramatically expanded preventive options over the past several years.

IV lidocaine is better viewed as a specialized rescue or cycle-breaking option for certain refractory cases rather than a competitor to these standard therapies.

Who might be considered for inpatient lidocaine?

There is no universal checklist guaranteeing that someone should receive IV lidocaine. In practice, specialists may consider intensive inpatient treatment when migraine is severely disabling, persistent, and unresponsive to multiple appropriate outpatient strategies.

A headache specialist would normally review previous preventive treatments, acute medication use, medication-overuse headache, cardiovascular health, other neurological diagnoses, current prescriptions, and possible contraindications before recommending an infusion.

People with heart rhythm disorders, significant liver or kidney problems, medication interactions, or other medical concerns may require additional caution or may not be candidates at all.

Anyone interested in lidocaine therapy should discuss it with a neurologist or headache specialist rather than trying to obtain the drug independently.

Why medication overuse should not be overlooked

One frustrating feature of chronic migraine is that the medications used to escape individual attacks can sometimes contribute to a cycle of increasing headache frequency when used too often.

Medication-overuse headache may occur when certain acute treatments are repeatedly taken across many days each month. The exact threshold depends on the medication. Triptans, opioids, and combination analgesics tend to become problematic at lower monthly usage frequencies than simple analgesics such as acetaminophen or some NSAIDs.

A headache diary recording headache days, migraine symptoms, medications, sleep, menstruation when relevant, and possible triggers can make patterns considerably easier for a physician to recognize.

Before assuming that an exotic new procedure is required, cleaning up an ineffective or overly complicated medication strategy can occasionally produce surprisingly meaningful improvement.

What the research means for people with chronic migraine

The excitement surrounding lidocaine comes primarily from the patients being studied. These are often people who have already exhausted multiple therapies. When nearly nine out of ten admissions in a large clinical series showed substantial acute improvement, headache specialists understandably noticed.

At the same time, the evidence does not yet support using IV lidocaine routinely for everyone with chronic migraine. Randomized controlled trials would help determine how much improvement is caused specifically by lidocaine, which patients are most likely to respond, what dosing strategy is ideal, and how long benefits really last.

The 2026 practice advisory essentially reflects this middle ground: lidocaine can be considered by experienced clinicians for intractable migraine in an appropriately monitored inpatient setting, but stronger evidence is still needed.

Experiences with chronic migraine and lidocaine treatment

Research statistics are important, but chronic migraine is ultimately lived one morning, meeting, school pickup, canceled dinner, and darkened bedroom at a time. The following scenarios illustrate the types of experiences commonly encountered in clinical practice and patient communities. They are composites for educational purposes rather than descriptions of specific individuals.

The patient who has tried almost everything

Imagine a 42-year-old professional who has had migraine since college. At first, attacks occurred once or twice a month. Years later, headache is present on 25 days of every month. On the worst days, opening a laptop feels like staring directly into a miniature sun.

She has tried topiramate, two CGRP medications, Botox, several triptans, a gepant, magnesium, dietary experiments, physical therapy, and enough headache diaries to qualify for a minor degree in spreadsheet management.

Some treatments help temporarily. None breaks the cycle.

This is closer to the type of patient represented in studies of inpatient lidocaine than someone who experiences two straightforward migraine attacks per month. Following specialist evaluation, she might be admitted for several days of intensive treatment. Lidocaine could be one component alongside other medications and careful monitoring.

If her pain drops from 8 out of 10 to 2 during hospitalization, that is meaningfulbut doctors still have another job: creating a post-discharge preventive plan so the improvement does not disappear as soon as normal life resumes.

When dramatic short-term relief does not last

Another common experience with cycle-breaking treatments is rapid improvement followed by partial recurrence.

A patient may enter the hospital with continuous headache, experience several dramatically better days during an infusion, and then notice symptoms creeping back during the following weeks. That outcome does not necessarily mean the treatment was useless.

For someone who has been trapped in an uninterrupted migraine state, temporary relief can restore sleep, eating habits, physical activity, and the ability to tolerate preventive therapies. It can function as a bridge rather than a permanent solution.

However, temporary improvement also explains why researchers measure outcomes weeks or months later instead of celebrating only the pain score at hospital discharge.

The patient who does not respond

Another patient may complete an infusion and notice little improvement. This experience is equally real.

Migraine is biologically diverse. A treatment that seems miraculous for one person may produce nothing beyond nausea and several boring hospital meals for another. Even medications supported by excellent randomized trials do not work for everyone.

Nonresponse should prompt reassessment rather than blame. A specialist may reconsider the diagnosis, look for medication overuse, evaluate sleep or neck-related contributors, adjust preventive treatment, consider different migraine-specific therapies, or investigate whether another headache disorder is present.

Why keeping a headache diary matters after treatment

Patients sometimes judge treatment using one question: “Does my head still hurt?” For chronic migraine, that can hide important improvement.

Suppose someone goes from 28 headache days to 20. They still have frequent headaches, so emotionally it may feel like failure. Yet eight additional headache-free days every month equals approximately 96 additional headache-free days over a year if the benefit continues.

A diary can also reveal that severe migraine days dropped from 15 to five, rescue medication use declined, or attacks became shorter even though total headache frequency changed less dramatically.

Tracking headache days, migraine days, pain severity, function, acute medication use, and side effects provides a far more useful picture than memory alone.

The emotional side of finally finding some relief

People without chronic migraine sometimes underestimate what repeated pain does to everyday decision-making. Patients may stop making plans because they are tired of canceling them. Careers can suffer. Relationships become harder. Parents feel guilty about missed activities. Sleep becomes unpredictable.

For that reason, even partial improvement can be emotionally powerful. Being able to attend a child’s game, finish a full workday, drive without severe light sensitivity, or simply wake up without immediately calculating pain intensity can feel enormous.

That perspective helps explain the interest in lidocaine despite the imperfect evidence. Refractory chronic migraine leaves some patients with relatively few remaining options. A treatment does not need to be magical to be valuable; it needs to create meaningful improvement without unacceptable risk.

When should you see a doctor about frequent migraine?

Schedule a medical evaluation if headaches are becoming more frequent, are interfering with work or daily activities, require acute medication several days per week, or are no longer responding to your usual treatment.

A neurologist or headache specialist may be especially helpful when migraine has become chronic or several preventive therapies have failed.

Seek urgent medical evaluation for a sudden explosive headache that reaches maximum intensity rapidly, a major new or unusual headache pattern, headache following significant head trauma, or headache accompanied by symptoms such as weakness, fainting, confusion, seizure, high fever, or new difficulty speaking or seeing. Those features can represent conditions other than migraine and should not simply be treated as another routine attack.

Conclusion

Lidocaine is an old medication finding a surprisingly modern role in migraine research. Continuous intravenous lidocaine has produced impressive short-term pain reductions in observational studies of people with refractory chronic migraine, while controlled trials of lidocaine-containing nerve blocks offer additional evidence that local anesthetic strategies can influence migraine symptoms.

Still, the headline requires an asterisk. The strongest evidence for prolonged IV lidocaine remains limited by the absence of large randomized controlled trials. Current expert guidance treats it as a specialized inpatient option for carefully selected people with intractable migrainenot a standard first-line treatment.

Research into nerve blocks, systemic infusion, and newer middle meningeal artery approaches could eventually clarify which patients benefit most and how long that benefit lasts. For now, the most useful takeaway is hopeful but measured: a common anesthetic may provide meaningful relief when conventional migraine therapies fail, but treatment must be individualized and medically supervised.

Note: This article is for informational purposes only and is not a substitute for diagnosis or treatment from a qualified healthcare professional. Intravenous or intra-arterial lidocaine can cause serious toxicity and should only be administered in appropriately monitored medical settings.